Monoclonal antibodies to fibroblast growth factor receptor 2
US10138301B2 · kind B2 · utility
1Cited by
8References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2017 |
| Grant date | Nov 27, 2018 |
| Priority date | — |
| Expiry date | Aug 10, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.